Subcellular tracking of drug release from carbon nanotube vehicles in living cells

The direct observation of drug release from carbon nanotube vehicles in living cells is realized through a unique two-dye labeling approach. Single-walled carbon nanotubes (SWNTs) are firstly marked with fluorescein isothiocyanate (FITC) to track their location and movement inside the cell. Then a fluorescent anticancer drug doxorubicin (DOX) is attached by means of π-stacking onto SWNTs. Delivered by SWNTs into cells, DOX will detach from the vehicle in an acidic environment due to the pH-dependent π-π stacking interaction between DOX and SWNTs. From observation of the two different kinds of fluorescence (green and red) that respectively represent the carrier SWNTs and drug DOX, the process of drug release inside the living cell can be monitored under a confocal microscope. Results show that the drug DOX detaches from SWNTs inside the lysosomes to yield free molecules and escape into the cytoplasm and finally into the nucleus, while the vehicle SWNTs are trapped inside the lysosomes, without entering the nucleus. The current observations confirm previously proposed mechanisms for drug/DOX release inside cells. The experimental establishment of drug-release mechanisms in living cells here might provide important insights for future design of new drug-delivery and release systems.     

Preparation and optimization of doxorubicin-loaded albumin nanoparticles using response surface methodology

Background: The objective of this work was to optimize the preparation of doxorubicin-loaded albumin nanoparticles (Dox-A-Nps) through desolvation procedures using response surface methodology (RSM). A central composite design (CCD) for four factors at five levels was used in this study.

Method: Albumin nanoparticles were prepared through a desolvation method and were optimized in the aid of CCD. Albumin concentration, amount of doxorubicin, pH values, and percentage of glutaraldehyde were selected as independent variables, particle size, zeta potential, drug loading, encapsulation efficiency, and nanoparticles yield were chosen as response variables. RSM and multiple response optimizations utilizing a quadratic polynomial equation were used to obtain an optimal formulation.

Results: The optimal formulation for Dox-A-Nps was composed of albumin concentration of 17?mg/ml, amount of doxorubicin of 2?mg/ml, pH value is 9 and percentage of glutaraldehyde of 125% of the theoretic amount, under which the optimized conditions gave rise to the actual average value of mean particle size (151?±?0.43?nm), zeta potential (?18.8?±?0.21 mV), drug loading efficiency (21.4?±?0.70%), drug entrapment efficiency (76.9?±?0.21%) and nanoparticles yield (82.0?±?0.34%). The storage stability experiments proved that Dox-A-Nps stable in 4°C over the period of 4 months. The in vitro experiments showed a burst release at the initial stage and followed by a prolonged release of Dox from albumin nanoparticles up to 60?h.

Conclusions: This study showed that the RSM-CCD method could efficiently be applied for the modeling of nanoparticles, which laid the foundation of the further research of immuno nanoparticles.     

酶法制备壳寡糖及其抗肿瘤活性评价

为进一步分析壳寡糖抗肿瘤活性及其机制,采用酶法制备工艺获取组分清晰的壳寡糖,优化酶解条件为酶解时间4 h、加酶量120 U/g,结合乙醇沉淀、超滤和纳滤联用的工艺获得聚合度2～4的壳寡糖。比较评价壳寡糖及其与阿霉素联用对3种肿瘤细胞的抑制效果,其中作用最为明显的人乳腺癌MDA-MB-231的细胞生存率降低20%。利用细胞迁移实验和激光共聚焦分析机制,得出壳寡糖可抑制MDA-MB-231细胞迁移并促进阿霉素入核。由此说明,壳寡糖可增强MDA-MB-231细胞对阿霉素的敏感性。     

Cytotoxicity Evaluation of a New Set of 2-Aminobenzo[de]iso-quinoline-1,3-diones

A new series of 2-amino-benzo[de]isoquinoline-1,3-diones was synthesized and fully characterized in our previous paper. Here, their cytotoxic effects have been evaluated in vitro in relation to colon HCT-116, hepatocellular Hep-G2 and breast MCF-7 cancer cell lines, using a crystal violet viability assay. The IC₅₀-values of the target compounds are reported in µg/mL, using doxorubicin as a reference drug. The findings revealed that compounds 14, 15, 16, 21 and 22 had significant cytotoxic effects against HCT-116, MCF-7 and Hep-G2 cell lines. Their IC₅₀ values ranged between 1.3 and 8.3 μg/mL in relation to doxorubicin (IC₅₀ ≈ 0.45–0.89 μg/mL). Therefore, these compounds could be used as templates for furthering the development and design of more potent antitumor agents through structural modification.     

Preliminary Study of Conformation and Drug Release Mechanism of Doxorubicin-Conjugated Glycol Chitosan, via cis-Aconityl Linkage, by Molecular Modeling

An investigation of the structure and drug release mechanism of a drug delivery system is proposed on the basis of semi-empirical and ab initio computations in vacuum stage. Cis-aconityl linkage is used to improve the interaction between an anti-cancer agent, doxorubicin, and a glycol chitosan biopolymer. It has been found that the doxorubicin-conjugated glycol chitosan carrier has more stability. The stability is increased when the lengths of the polyethylene glycol (PEG) chains in the glycol chitosan biopolymer are increased. Cis-aconityl can release doxorubicin under appropriate environmental conditions. Relative energies of this mechanism in an acid condition, as determined by B3LYP/6-31G//PM3, are 122.41, 119.27, 160.18 and 222.22 kcal/mol, and by the B3LYP/6-31G//HF/6-31G method are 54.23, 109.28, 219.98 and 980.49 kcal/mol, with mono-, di-, tri-, and quanta-ethylene glycol, respectively. In a normal condition, the relative energies are above 300 kcal/mol for all reactions. Therefore, cis-aconityl will release doxorubicin in an acid solution but not in a normal condition. The glycol chitosan polymer can be degraded in an acid solution as well. Long PEG chains influence the release mechanism of doxorubicin. The proposed length of the PEG chain is di-ethylene glycol. These simulation results agree well with various reported experimental data.     

Tetrazine‐Responsive Self‐immolative Linkers

Molecules that undergo activation or modulation following the addition of benign external small‐molecule chemical stimuli have numerous applications. Here, we report the highly efficient “decaging” of a variety of moieties by activation of a “self‐immolative” linker, by application of water‐soluble and stable tetrazine, including the controlled delivery of doxorubicin in a cellular context.     

Poly(N-isopropylacrylamide)-coated β-cyclodextrin–capped magnetic mesoporous silica nanoparticles exhibiting thermal and pH dual response for triggered anticancer drug delivery

In this research a novel controlled anticancer drug delivery system with dual pH and thermal responses was designed based on magnetic mesoporous silica nanoparticles that were anchored by β-cyclodextrin and coated by poly(N-isopropylacrylamide) (PNIPAM). Results demonstrated that the behavior of doxorubicin (anticancer drug) release depended on pH and temperature conditions. At endosomal pH (pH 5.5) the amount of drug release enhanced because the cap was removed from the pores. Furthermore, PNIPAM shell collapsed above the lower critical solution temperature and the releasing of drug increased. Thus, this nanocarrier would have the potential to be applied in the tumor therapy.     

ATP‐Responsive Aptamer‐Based Metal–Organic Framework Nanoparticles (NMOFs) for the Controlled Release of Loads and Drugs

Nanoparticles consisting of metal–organic frameworks (NMOFs) modified with nucleic acid binding strands are synthesized. The NMOFs are loaded with a fluorescent agent or with the anticancer drug doxorubicin, and the loaded NMOFs are capped by hybridization with a complementary nucleic acid that includes the ATP‐aptamer or the ATP‐AS1411 hybrid aptamer in caged configurations. The NMOFs are unlocked in the presence of ATP via the formation of ATP‐aptamer complexes, resulting in the release of the loads. As ATP is overexpressed in cancer cells, and since the AS1411 aptamer recognizes the nucleolin receptor sites on the cancer cell membrane, the doxorubicin‐loaded NMOFs provide functional carriers for targeting and treatment of cancer cells. Preliminary cell experiments reveal impressive selective permeation of the NMOFs into MDA‐MB‐231 breast cancer cells as compared to MCF‐10A normal epithelial breast cells. High cytotoxic efficacy and targeted drug release are observed with the ATP‐AS1411‐functionalized doxorubicin‐loaded NMOFs.